Literature DB >> 23307680

Heterotopic ossification following total hip replacement for acetabular fractures.

O Chémaly1, J Hebert-Davies, D M Rouleau, B Benoit, G Y Laflamme.   

Abstract

Early total hip replacement (THR) for acetabular fractures offers accelerated rehabilitation, but a high risk of heterotopic ossification (HO) has been reported. The purpose of this study was to evaluate the incidence of HO, its associated risk factors and functional impact. A total of 40 patients with acetabular fractures treated with a THR weres retrospectively reviewed. The incidence and severity of HO were evaluated using the modified Brooker classification, and the functional outcome assessed. The overall incidence of HO was 38% (n = 15), with nine severe grade III cases. Patients who underwent surgery early after injury had a fourfold increased chance of developing HO. The mean blood loss and operating time were more than twice that of those whose surgery was delayed (p = 0.002 and p < 0.001, respectively). In those undergoing early THR, the incidence of grade III HO was eight times higher than in those in whom THR was delayed (p = 0.01). Only three of the seven patients with severe HO showed good or excellent Harris hip scores compared with eight of nine with class 0, I or II HO (p = 0.049). Associated musculoskeletal injuries, high-energy trauma and head injuries were associated with the development of grade III HO.The incidence of HO was significantly higher in patients with a displaced acetabular fracture undergoing THR early compared with those undergoing THR later and this had an adverse effect on the functional outcome.

Entities:  

Mesh:

Year:  2013        PMID: 23307680     DOI: 10.1302/0301-620X.95B1.29721

Source DB:  PubMed          Journal:  Bone Joint J        ISSN: 2049-4394            Impact factor:   5.082


  8 in total

Review 1.  Management of acetabular fractures in elderly patients.

Authors:  Nikhil Shah; Inder P Gill; Vijaya Kumar Hosahalli Kempanna; Mohammad R Iqbal
Journal:  J Clin Orthop Trauma       Date:  2020-10-19

2.  Acute revision hip arthroplasty: a previously unrecognized risk factor for heterotopic ossification.

Authors:  Abdulaziz Aljurayyan; Dylan Tanzer; Michael Tanzer
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-01-02

Review 3.  [Hip endoprosthetics in osteoarthritis after acetabular fractures].

Authors:  W Schneiders; A Hartmann; T Meyner; K-P Günther
Journal:  Orthopade       Date:  2015-07       Impact factor: 1.087

4.  Predicting the Poor Clinical and Radiographic Outcomes after the Anatomical Reduction and Internal Fixation of Posterior Wall Acetabular Fractures: A Retrospective Analysis.

Authors:  Sung-Yen Lin; Cheng-Jung Ho; Wen-Chih Liu; Jr-Kai Chen; Hung-Pin Tu; Tien-Ching Lee; Je-Ken Chang; Chung-Hwan Chen; Cheng-Chang Lu
Journal:  J Clin Med       Date:  2022-06-06       Impact factor: 4.964

5.  Safety of total hip arthroplasty for femoral neck fractures using the direct anterior approach: a retrospective observational study in 86 elderly patients.

Authors:  Grégoire Thürig; Jürgen Wilfried Schmitt; Ksenija Slankamenac; Clément M L Werner
Journal:  Patient Saf Surg       Date:  2016-05-06

6.  Should Total Hip Arthroplasty be Performed Acutely in the Treatment of Acetabular Fractures in Elderly or Used as a Salvage Procedure Only?

Authors:  Katharine Hamlin; Gabija Lazaraviciute; Michalis Koullouros; Tarak Chouari; Iain M Stevenson; Steven W Hamilton
Journal:  Indian J Orthop       Date:  2017 Jul-Aug       Impact factor: 1.251

7.  Acute total hip arthroplasty for older patients with acetabular fractures: A meta-analysis.

Authors:  Julio J Jauregui; Tristan B Weir; Jin F Chen; Aaron J Johnson; Neil R Sardesai; Aditya V Maheshwari; Theodore T Manson
Journal:  J Clin Orthop Trauma       Date:  2020-01-09

8.  Abundant heterotopic bone formation following use of rhBMP-2 in the treatment of acetabular bone defects during revision hip arthroplasty.

Authors:  Alexander Arzeno; Tim Wang; James I Huddleston
Journal:  Arthroplast Today       Date:  2018-01-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.